



Nicox completes the acquisition of Acieux Therapeutics, Inc.

October 27, 2014.

Sophia Antipolis, France.

Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Acieux Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company. This acquisition represents a significant step forward in Nicox's strategy of creating an international ophthalmic company and will significantly broaden and strengthen Nicox's therapeutic development pipeline.

For more information, please refer to:

- Press release dated July 2, 2014: [Nicox to acquire Acieux Therapeutics, Inc.](#)
 - Press release dated October 22, 2014: [Nicox's shareholders approve acquisition of Acieux Therapeutics, Inc.](#)
 - ['Document E'](#) registered with the French *Autorité des Marchés Financiers* (AMF) on September 30, 2014 (E.14-060) (in French, available on Nicox's website www.nicox.com in the 'Investor Information' / 'Shareholder meetings' section).
-

About Nicox



Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company's commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox's key proprietary asset in ophthalmology is VESNEO (latanoprostene bunod), a novel compound based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit www.nicox.com.

.....

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in: the 4th chapter of the "Document de référence, rapport financier annuel et rapport de gestion 2013" filed with the French Autorité des Marchés Financiers (AMF) on April 2nd, 2014; the "Rapport semestriel financier et d'activité au 30 juin 2014"; the 5th chapter of the "Actualisation du Document de Référence 2013" filed with the AMF on September 30, 2014 (D. 14-0271-A01); and the section B of the 'Document E' registered with the AMF on September 30, 2014 (E.14-060). All these documents are available on Nicox's website (www.nicox.com).

.....

Contacts



Nicox

Gavin Spencer | Executive Vice President Corporate Development
+33 (0)4 97 24 53 00 | communications@nicox.com

Media Relations

United Kingdom

Jonathan Birt
+44 7860 361 746 | jonathan.birt@ymail.com

France

Caroline Courme | Communication Manager
+33 (0)4 97 24 53 43 | courme@nicox.com